A Study of SDI-118 in Participants in Remission From Depression
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the
safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on
male and female study participants reporting with cogntive decline and who in remission from
depression.